Literature DB >> 25368621

On the Non-Redundant Roles of TDO2 and IDO1.

Paolo Puccetti1.   

Abstract

Entities:  

Keywords:  AhR; IDO1; TDO2; indoleamine 2,3-dioxygenase; tryptophan

Year:  2014        PMID: 25368621      PMCID: PMC4202388          DOI: 10.3389/fimmu.2014.00522

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


× No keyword cloud information.
The Perspective by Pallotta et al. (1) offers the opportunity of a few more considerations on the mutually supportive relationship between tryptophan catabolic enzymes and the aryl hydrocarbon receptor (AhR) in the transitional response aimed at reinstalling homeostatic tolerance after meeting the needs of an acute inflammatory reaction (2). One major question is in fact – Why does AhR need two distinct sources of the ligand kynurenine to become activated, namely, tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase (IDO1) (3)? (The third known tryptophan catabolic enzyme, IDO2, has limited catalytic activity relative to the two others.). The IDO1AhR axis would, in fact, appear to be a highly efficient mechanism per se, in that it acts in a feedforward loop [i.e., kynurenine is an activating ligand for AhR, and activated AhR promotes Ido1 transcription (4)], and it is self-regulated [AhR presides over regulatory proteolysis of IDO1, to restore homeostasis, as proposed by Pallotta et al. (1)]. For this loop to be operative, one need must be absolutely met, namely, the absence of IL-6, which operates its own mode of IDO1 proteasomal degradation via induction of SOCS3, resulting in the enzyme ubiquitination and proteolysis (5). Although it is one of AhR’s multiple jobs to transcriptionally repress Il6 – through transcription of Il10 (6) – the AhRIDO1 system is IL-6-sensitive, and the “early” kynurenine leading to the recruitment of IL-10 to the transitional response must derive from a source other than the IDO1AhR axis, that is, an enzyme not amenable to suppression by IL-6. At the onset of an inflammatory response, IL-6 production is a necessary, defensive mechanism that need not be abrogated till the onset of the transition that will contribute to reinstall an optimal balance between inflammation and tolerance. Among the early events of systemic inflammation is cortisol-driven induction of acute phase proteins in liver. TDO2 is one such protein, and it is synthesized when production of proinflammatory cytokines, including IL-6, is at its height. Tdo2 is not under AhR transcriptional control, nor is TDO2 amenable to IL-6-driven proteasomal degradation (3). This makes TDO2 production of kynurenine – and AhR activation – compatible with the events initiating the transitional response (Figure 1).
Figure 1

Sequential events marking the transitional response aimed at reinstalling homeostatic tolerance after meeting the needs of an acute inflammatory reaction, with TDO2 and IDO1 having temporally segregated roles.

Sequential events marking the transitional response aimed at reinstalling homeostatic tolerance after meeting the needs of an acute inflammatory reaction, with TDO2 and IDO1 having temporally segregated roles. The conclusion is that the roles of TDO2 and IDO1 as a source of AhR ligands are not redundant, the major differences lying in the different modalities of their respective gene activation, their being temporally segregated in function, and their disparate susceptibilities to inhibition by IL-6.

Conflict of Interest Statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  6 in total

Review 1.  The aryl hydrocarbon receptor: multitasking in the immune system.

Authors:  Brigitta Stockinger; Paola Di Meglio; Manolis Gialitakis; João H Duarte
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

Review 2.  Tissue damage control in disease tolerance.

Authors:  Miguel P Soares; Raffaella Gozzelino; Sebastian Weis
Journal:  Trends Immunol       Date:  2014-08-30       Impact factor: 16.687

3.  Aryl hydrocarbon receptor control of a disease tolerance defence pathway.

Authors:  Alban Bessede; Marco Gargaro; Maria T Pallotta; Davide Matino; Giuseppe Servillo; Cinzia Brunacci; Silvio Bicciato; Emilia M C Mazza; Antonio Macchiarulo; Carmine Vacca; Rossana Iannitti; Luciana Tissi; Claudia Volpi; Maria L Belladonna; Ciriana Orabona; Roberta Bianchi; Tobias V Lanz; Michael Platten; Maria A Della Fazia; Danilo Piobbico; Teresa Zelante; Hiroshi Funakoshi; Toshikazu Nakamura; David Gilot; Michael S Denison; Gilles J Guillemin; James B DuHadaway; George C Prendergast; Richard Metz; Michel Geffard; Louis Boon; Matteo Pirro; Alfonso Iorio; Bernard Veyret; Luigina Romani; Ursula Grohmann; Francesca Fallarino; Paolo Puccetti
Journal:  Nature       Date:  2014-07-10       Impact factor: 49.962

4.  Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase.

Authors:  Christoph F A Vogel; Samuel R Goth; Bin Dong; Isaac N Pessah; Fumio Matsumura
Journal:  Biochem Biophys Res Commun       Date:  2008-08-09       Impact factor: 3.575

5.  SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis.

Authors:  Ciriana Orabona; Maria T Pallotta; Claudia Volpi; Francesca Fallarino; Carmine Vacca; Roberta Bianchi; Maria L Belladonna; Maria C Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

Review 6.  AhR-Mediated, Non-Genomic Modulation of IDO1 Function.

Authors:  Maria Teresa Pallotta; Francesca Fallarino; Davide Matino; Antonio Macchiarulo; Ciriana Orabona
Journal:  Front Immunol       Date:  2014-10-15       Impact factor: 7.561

  6 in total
  3 in total

1.  Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer.

Authors:  Rumi Lee; Jiexi Li; Jun Li; Chang-Jiun Wu; Shan Jiang; Wen-Hao Hsu; Deepavali Chakravarti; Peiwen Chen; Kyle A LaBella; Jing Li; Denise J Spring; Di Zhao; Y Alan Wang; Ronald A DePinho
Journal:  Cancer Discov       Date:  2022-07-06       Impact factor: 38.272

Review 2.  Aspects of Tryptophan and Nicotinamide Adenine Dinucleotide in Immunity: A New Twist in an Old Tale.

Authors:  Hector Rodriguez Cetina Biefer; Anju Vasudevan; Abdallah Elkhal
Journal:  Int J Tryptophan Res       Date:  2017-06-14

3.  Differential Expression of Genes Involved in Metabolism and Immune Response in Diffuse and Intestinal Gastric Cancers, a Pilot Ptudy.

Authors:  Martine Perrot-Applanat; Cynthia Pimpie; Sophie Vacher; Ivan Bieche; Marc Pocard; Véronique Baud
Journal:  Biomedicines       Date:  2022-01-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.